Tango Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$0.53 | -$0.20 | -$0.31 |
| Q2 2024 | 2 | -$0.59 | -$0.22 | -$0.35 |
| Q3 2024 | 2 | -$0.63 | -$0.24 | -$0.37 |
| Q4 2024 | 7 | -$0.38 | -$0.26 | -$0.34 |
| Q1 2025 | 3 | -$0.39 | -$0.32 | -$0.36 |
| Q2 2025 | 2 | -$0.63 | -$0.24 | -$0.37 |
| Q3 2025 | 2 | -$0.64 | -$0.24 | -$0.37 |
| Q4 2025 | 2 | -$0.64 | -$0.24 | -$0.37 |
Tango Therapeutics, Inc. Earnings Date And Information
Tango Therapeutics, Inc. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-0.27 earnings per share for the quarter, topping analysts' consensus estimates of $-0.34 by $0.07. The company had revenue of 11.61 M for the quarter and had revenue of 36.53 M for the year. Tango Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-1.08 diluted earnings per share) and currently has a price-to-earnings ratio of -3.17. Tango Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 17th, 2025 based on prior year's report dates.
Tango Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | -$0.34 | -$0.27 | 0.07 | $8.07 M | $11.61 M |
| 08/07/2024 | Q2 2024 | -$0.34 | -$0.24 | 0.1 | $7.63 M | $19.88 M |
| 05/08/2024 | Q1 2024 | -$0.31 | -$0.35 | -0.04 | $6.47 M | |
| 03/18/2024 | Q4 2023 | -$0.28 | -$0.32 | -0.04 | $5.43 M | |
| 11/08/2023 | Q3 2023 | -$0.34 | -$0.23 | 0.11 | $7.59 M | $10.73 M |
| 08/07/2023 | Q2 2023 | -$0.35 | -$0.23 | 0.12 | $7.19 M | $14.60 M |
| 05/09/2023 | Q1 2023 | -$0.36 | -$0.29 | 0.07 | $5.77 M | |
| 03/27/2023 | Q4 2022 | -$0.33 | $6.41 M | |||
| 11/10/2022 | Q3 2022 | -$0.32 | -$0.32 | 0 | $5.64 M | $6.92 M |
| 08/10/2022 | Q2 2022 | -$0.33 | -$0.28 | 0.05 | $5.66 M | $5.77 M |
| 05/11/2022 | Q1 2022 | -$0.28 | -$0.29 | -0.01 | $5.76 M | |
| 03/28/2022 | Q4 2021 | -$0.25 | $5.72 M | |||
| 11/09/2021 | Q3 2021 | -$0.28 | -$0.28 | 0 | $6.51 M | $6.79 M |
| 08/06/2021 | Q2 2021 | -$0.05 | $18.15 M | |||
| 05/14/2021 | Q1 2021 | -$0.14 | $6.39 M | |||
| 03/31/2021 | Q4 2020 | -$0.53 | $9.14 M | |||
| 11/13/2020 | Q3 2020 | -$0.31 | $-11,261,000 | |||
| 06/29/2020 | Q2 2020 | -$0.75 | $5.06 M | |||
| 03/30/2020 | Q1 2020 | -$0.74 | $4.71 M |
Tango Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Tango Therapeutics, Inc.'s earnings date?
Tango Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 17th, 2025 based off last year's report dates.
-
Did Tango Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Tango Therapeutics, Inc. (:TNGX) reported $-0.27 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.34 by $0.07.
-
How can I listen to Tango Therapeutics, Inc.'s earnings conference call?
The conference call for Tango Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Tango Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Tango Therapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Tango Therapeutics, Inc. generate each year?
Tango Therapeutics, Inc. (:TNGX) has a recorded annual revenue of $36.53 M.
-
How much profit does Tango Therapeutics, Inc. generate each year?
Tango Therapeutics, Inc. (:TNGX) has a recorded net income of $36.53 M. Tango Therapeutics, Inc. has generated $-1.08 earnings per share over the last four quarters.
-
What is Tango Therapeutics, Inc.'s price-to-earnings ratio?
Tango Therapeutics, Inc. (:TNGX) has a price-to-earnings ratio of -3.17 and price/earnings-to-growth ratio is 0.9.
